HighTide Therapeutics Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	59.1	81.23	136.67	43.43	48.06
Research & Development	164.47	363.53	311.57	182.65	84.01
Operating Expenses	223.57	444.75	448.24	226.08	132.08
Operating Income	-223.57	-444.75	-448.24	-226.08	-132.08
Interest Expense	-2.36	-1.53	-0.4	-0.43	-4.53
Interest & Investment Income	-	29.18	24.28	12.38	3.33
Currency Exchange Gain (Loss)	-	3.12	-0.89	-7.52	0.6
Other Non Operating Income (Expenses)	-5.95	38.79	8.17	8.2	5.28
EBT Excluding Unusual Items	-231.88	-375.2	-417.07	-213.45	-127.39
Gain (Loss) on Sale of Investments	-	-6.11	-	-	-
Gain (Loss) on Sale of Assets	-	-0.21	-	-	-0
Other Unusual Items	-	-	-522.16	23.24	-93.66
Pretax Income	-231.88	-381.52	-939.23	-190.21	-221.05
Income Tax Expense	0.22	0.27	0.08	0.03	0.1
Earnings From Continuing Operations	-232.1	-381.79	-939.31	-190.24	-221.15
Minority Interest in Earnings	-12.87	-	-	-	-
Net Income	-244.97	-381.79	-939.31	-190.24	-221.15
Net Income to Common	-244.97	-381.79	-939.31	-190.24	-221.15
Shares Outstanding (Basic)	480	452	260	255	42
Shares Outstanding (Diluted)	480	452	260	255	42
Shares Change (YoY)	6.25%	74.08%	1.91%	506.17%	-
EPS (Basic)	-0.51	-0.84	-3.62	-0.75	-5.26
EPS (Diluted)	-0.51	-0.84	-3.62	-0.75	-5.26
Free Cash Flow	-	-302.75	-357.42	-172.56	-92.29
Free Cash Flow Per Share	-	-0.67	-1.38	-0.68	-2.19
EBITDA	-222.56	-443.75	-447.7	-225.68	-131.8
D&A For EBITDA	1.01	1.01	0.54	0.41	0.28
EBIT	-223.57	-444.75	-448.24	-226.08	-132.08

Source: S&P Global Market Intelligence. Standard template. Financial Sources.